Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme

Table 3

Univariate and multivariate analysis of prognostic factors for overall survival in 176 patients with recurrent glioblastoma multiforme.

	Univariate effect			Multivariate effect
	HR	95% CI		HR	95% CI
Gender
Female	1			1
Male	0.97	(0.71–1.56)	0.91	1.41	(0.80–1.74)	0.25
Age (years)	0.90	(0.72–1.26)	0.79	0.85	(0.65–1.31)	0.61
KPS score, (%)
<70	1			1
≥70	0.63	(0.45–0.89)	0.01	0.58	(0.39–0.76)	0.01
Steroid use
No	1
Yes	0.90	(0.71–1.27)	0.85	0.81	(0.62–1.27)	0.63
Type of first surgery, (%)
Biopsy/partial resection	1			1
Subtotal/total resection	0.76	(0.38–1.23)	0.51	0.82	(0.49–1.38)	0.74
MGMT status
Unmethylated	1			1
Methylated	0.95	(0.67–1.35)	0.82	0.88	(0.58–1.26)	0.71
Time from original diagnosis (months)
<12	1			1
≥12	1.54	(0.64–2.09)	0.46	1.41	(0.69–1.99)	0.53
Second surgery before treatment
No	1
Yes	0.87	(0.57–1.31)	0.90
Maximum tumor diameter (mm)	0.73	(0.45–1.39)	0.47